Literature DB >> 14568892

Effects of statins on platelet inhibition by a high loading dose of clopidogrel.

Iris Müller1, Felicitas Besta, Christian Schulz, Zhongyan Li, Steffen Massberg, Meinrad Gawaz.   

Abstract

BACKGROUND: Recent studies suggested that some HMG-CoA reductase blockers might inhibit the antiplatelet activity of clopidogrel. Therefore, we analyzed how various statins together with a high loading dose of clopidogrel (600 mg) affect platelet aggregation. METHODS AND
RESULTS: Seventy-seven patients with stable angina scheduled for elective coronary stenting were studied. Patients were randomized to receive atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin (each 20 mg), cerivastatin (0.3 mg), or placebo, plus a high loading dose of 600 mg of clopidogrel. ADP-induced platelet aggregation (5 and 20 micromol/L) was determined before and 2 and 4 hours after first clopidogrel administration. All patients were taking aspirin (100 mg/d) regularly. We found that none of the statins significantly influenced inhibition of platelet aggregation by clopidogrel.
CONCLUSIONS: Concomitant use of statins with clopidogrel does not significantly inhibit antiplatelet activity, at least when clopidogrel is administered at a high loading dose of 600 mg.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568892     DOI: 10.1161/01.CIR.0000099507.32936.C0

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  [Interaction of statins with clopidogrel].

Authors:  W Von Scheidt
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

2.  Percutaneous coronary intervention: recommendations for good practice and training.

Authors:  K D Dawkins; T Gershlick; M de Belder; A Chauhan; G Venn; P Schofield; D Smith; J Watkins; H H Gray
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

3.  Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.

Authors:  Jacques Turgeon; Chantal Pharand; Véronique Michaud
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

Review 4.  Platelet activation, and antiplatelet targets and agents: current and novel strategies.

Authors:  Yao-Zu Xiang; Ye Xia; Xiu-Mei Gao; Hong-Cai Shang; Li-Yuan Kang; Bo-Li Zhang
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

6.  Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.

Authors:  Gergely Feher; Katalin Koltai; Elod Papp; Balint Alkonyi; Alexander Solyom; Peter Kenyeres; Gabor Kesmarky; Laszlo Czopf; Kalman Toth
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.

Authors:  Morten Schmidt; Martin B Johansen; Michael Maeng; Anne Kaltoft; Lisette O Jensen; Hans-Henrik Tilsted; Hans E Bøtker; John A Baron; Henrik Toft Sørensen
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

8.  Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.

Authors:  Anja Zahno; Karin Brecht; Michael Bodmer; Daniel Bur; Dimitrios A Tsakiris; Stephan Krähenbühl
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Clinical importance of aspirin and clopidogrel resistance.

Authors:  Gergely Feher; Andrea Feher; Gabriella Pusch; Katalin Koltai; Antal Tibold; Beata Gasztonyi; Elod Papp; Laszlo Szapary; Gabor Kesmarky; Kalman Toth
Journal:  World J Cardiol       Date:  2010-07-26

10.  Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

Authors:  Christoph Varenhorst; Stefan James; David Erlinge; John T Brandt; Oscar O Braun; Michael Man; Agneta Siegbahn; Joseph Walker; Lars Wallentin; Kenneth J Winters; Sandra L Close
Journal:  Eur Heart J       Date:  2009-05-09       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.